scholarly journals Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study

2016 ◽  
Vol 5 (3) ◽  
pp. e145 ◽  
Author(s):  
Poobalan Naidoo ◽  
Jeffrey Wing ◽  
Virendra Rambiritch
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Trial Protocol ◽  
Multicenter Clinical Trial ◽  
Double Blind ◽  
Clinical Trial Protocol

scholarly journals Sleeve gastrectomy versus Roux-en-Y gastric bypass for type 2 diabetes and morbid obesity: double-blind randomised clinical trial protocol

BMJ Open ◽  
2016 ◽  
Vol 6 (7) ◽  
pp. e011416 ◽  
Author(s):  
Rinki Murphy ◽  
Nicholas J Evennett ◽  
Michael G Clarke ◽  
Steven J Robinson ◽  
Lee Humphreys ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Morbid Obesity ◽  
Gastric Bypass ◽  
Sleeve Gastrectomy ◽  
Randomised Clinical Trial ◽  
Trial Protocol ◽  
Double Blind ◽  
Clinical Trial Protocol

Effectiveness of the piperine-supplemented Curcuma longa L. in metabolic control of patients with type 2 diabetes: a randomised double-blind placebo-controlled clinical trial

2021 ◽  
pp. 1-10
Author(s):  
Joana Furtado de Figueiredo Neta ◽  
Vivian Saraiva Veras ◽  
Danilo Ferreira de Sousa ◽  
Maria da Conceição dos Santos Oliveira Cunha ◽  
Maria Veraci Oliveira Queiroz ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Metabolic Control ◽  
Curcuma Longa ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma

2021 ◽  
Vol 28 (1) ◽  
pp. 726-739
Author(s):  
Masazumi Fujii ◽  
Masao Kobayakawa ◽  
Kiyoshi Saito ◽  
Akihiro Inano ◽  
Akio Morita ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Neurofibromatosis Type ◽  
Primary Objective ◽  
Neurofibromatosis Type 2 ◽  
Efficacy And Safety ◽  
Multicenter Clinical Trial ◽  
Double Blind ◽  
Hearing Function ◽  
Initial Intervention

Neurofibromatosis type 2 (NF2) causes bilateral vestibular schwannomas (VSs), leading to deafness. VS is treated by surgery or radiation, but neither treatments prevent hearing loss. Bevacizumab was found to be effective in suppressing the tumor’s growth and may help to improve hearing. We are conducting a randomized, double-blind, multicenter clinical trial to verify the efficacy and safety of bevacizumab in NF2-related VS. The primary objective is to evaluate the efficacy of bevacizumab in improving hearing in the affected ear. One of the secondary objectives is to evaluate bevacizumab’s efficacy in rechallenge treatment in relapsed cases. Sixty patients will randomly receive either bevacizumab or a placebo and will be clinically observed for 48 weeks in the initial intervention phase. In the first half (24 weeks), they will receive either 5 mg/kg of bevacizumab or a placebo drug. In the second half, all patients will receive 5 mg/kg of bevacizumab. If hearing function deteriorated in a patient who had shown improvement during the first phase, a rechallenge dose with bevacizumab would be offered.

scholarly journals Effect of vitamin D on insulin resistance and anthropometric parameters in Type 2 diabetes; a randomized double-blind clinical trial

2012 ◽  
Vol 20 (1) ◽  
Author(s):  
Ramin Heshmat ◽  
Ozra Tabatabaei-Malazy ◽  
Shabnam Abbaszadeh-Ahranjani ◽  
Samimeh Shahbazi ◽  
Ghazal Khooshehchin ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Vitamin D ◽  
Anthropometric Parameters ◽  
Double Blind ◽  
Double Blind Clinical Trial
Sign in / Sign up

Export Citation Format

Share Document